Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that AstraZeneca's Exanta will revolutionize the prevention of stroke in cases of atrial fibrillation. Sales of Exanta will reach more than $1.5 billion in 2007 and surpass $2.4 billion in 2012.
Exanta offers many advantages over currently marketed oral anticoagulants like Bristol-Myers Squibb's Coumadin--the current anticoagulant of choice for preventing stroke in atrial fibrillation. "Exanta can be given as a fixed oral dose, without the need for titration or regular anticoagulant monitoring; it also has a superior food- and drug- interaction profiles," said Ruth Brown, Ph.D., analyst at Decision Resources. "These advantages will not only allow Exanta to erode Coumadin's market share, they will also allow the extension of anticoagulant therapy to a much wider patient population, including the elderly, who are often excluded from such treatment regimens because of physician concerns about Coumadin's safety."
Disease Facts-Atrial Fibrillation
Atrial fibrillation is the cardiac arrhythmia most frequently encountered in clinical practice. The prevalence of the condition is 2 per 1,000 males and females aged 40 or older, and the number of prevalent cases is set to rise in the major pharmaceutical markets as a result of the aging population. Yet, despite the high prevalence of atrial fibrillation and the many problems associated with current therapies for this condition drug development pipelines for the disease are less robust than for other cardiovascular indications.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Atrial Fibrillation is a Cardium study.
About Decision Resources
Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030626/DECLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/